153 related articles for article (PubMed ID: 15995618)
1. [Current situation and problems of PET examinations].
Chihara H; Uozumi H
Nihon Hoshasen Gijutsu Gakkai Zasshi; 2005 Jun; 61(6):861-7. PubMed ID: 15995618
[TBL] [Abstract][Full Text] [Related]
2. [Oncology PET imaging].
Inubushi M
Igaku Butsuri; 2014; 34(1):3-9. PubMed ID: 25199271
[TBL] [Abstract][Full Text] [Related]
3. [Technical Approaches for Quantitative Treatment Responses Using 18F-FDG PET].
Miwa K; Miyaji N; Umeda T; Murata T; Wagatsuma K; Sasaki M
Igaku Butsuri; 2015; 35(1):30-8. PubMed ID: 26753394
[TBL] [Abstract][Full Text] [Related]
4. PET and [18F]-FDG in oncology: a clinical update.
Conti PS; Lilien DL; Hawley K; Keppler J; Grafton ST; Bading JR
Nucl Med Biol; 1996 Aug; 23(6):717-35. PubMed ID: 8940714
[TBL] [Abstract][Full Text] [Related]
5. (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization.
Vallabhajosula S
Semin Nucl Med; 2007 Nov; 37(6):400-19. PubMed ID: 17920348
[TBL] [Abstract][Full Text] [Related]
6. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
7. Improved detection of breast cancer on FDG-PET cancer screening using breast positioning device.
Kaida H; Ishibashi M; Fujii T; Kurata S; Ogo E; Tanaka M; Hayabuchi N
Ann Nucl Med; 2008 Feb; 22(2):95-101. PubMed ID: 18311533
[TBL] [Abstract][Full Text] [Related]
8. PET and cancer screening.
Yasuda S; Ide M
Ann Nucl Med; 2005 May; 19(3):167-77. PubMed ID: 15981668
[TBL] [Abstract][Full Text] [Related]
9. Clinical applications of positron emission tomography in sarcoma management.
Quak E; van de Luijtgaarden AC; de Geus-Oei LF; van der Graaf WT; Oyen WJ
Expert Rev Anticancer Ther; 2011 Feb; 11(2):195-204. PubMed ID: 21342039
[TBL] [Abstract][Full Text] [Related]
10. 18F-FDG PET/CT versus conventional investigations for cancer screening in autoimmune inflammatory myopathy in the era of novel myopathy classifications.
Maliha PG; Hudson M; Abikhzer G; Singerman J; Probst S
Nucl Med Commun; 2019 Apr; 40(4):377-382. PubMed ID: 30664602
[TBL] [Abstract][Full Text] [Related]
11. Performance profile of FDG-PET and PET/CT for cancer screening on the basis of a Japanese Nationwide Survey.
Minamimoto R; Senda M; Uno K; Jinnouchi S; Iinuma T; Ito K; Okuyama C; Oguchi K; Kawamoto M; Suzuki Y; Tsukamoto E; Terauchi T; Nakashima R; Nishio M; Nishizawa S; Fukuda H; Yoshida T; Inoue T
Ann Nucl Med; 2007 Nov; 21(9):481-98. PubMed ID: 18030580
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of whole-body cancer screening using 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography: a preliminary report.
Terauchi T; Murano T; Daisaki H; Kanou D; Shoda H; Kakinuma R; Hamashima C; Moriyama N; Kakizoe T
Ann Nucl Med; 2008 Jun; 22(5):379-85. PubMed ID: 18600415
[TBL] [Abstract][Full Text] [Related]
13. The pivotal role of FDG-PET/CT in modern medicine.
Hess S; Blomberg BA; Zhu HJ; Høilund-Carlsen PF; Alavi A
Acad Radiol; 2014 Feb; 21(2):232-49. PubMed ID: 24439337
[TBL] [Abstract][Full Text] [Related]
14. Pioneering and fundamental achievements on the development of positron emission tomography (PET) in oncology.
Fukuda H; Kubota K; Matsuzawa T
Tohoku J Exp Med; 2013 Jul; 230(3):155-69. PubMed ID: 23883588
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic efficacy of 18F-FDG-PET or PET/CT in breast cancer with suspected recurrence: a systematic review and meta-analysis.
Xiao Y; Wang L; Jiang X; She W; He L; Hu G
Nucl Med Commun; 2016 Nov; 37(11):1180-8. PubMed ID: 27428888
[TBL] [Abstract][Full Text] [Related]
16. [Understanding positon emission tomography (PET) with [18F]-FDG in clinical oncology. Informations dedicated to patients and relatives].
Bourguet P; Brusco S; Corone C; Devillers A; Foehrenbach H; Lumbroso JD; Maszelin P; Montravers F; Moretti JL; Rain JD; Talbot JN; Carretier J; Leichtnam-Dugarin L; Delavigne V; Philip T; Fervers B; ; ; ; ; ; ;
Bull Cancer; 2005 Jul; 92(7):723-32. PubMed ID: 16123010
[TBL] [Abstract][Full Text] [Related]
17. Positioning of 18F-fluorodeoxyglucose-positron emission tomography imaging in the management algorithm of hepatocellular carcinoma.
Kawamura E; Shiomi S; Kotani K; Kawabe J; Hagihara A; Fujii H; Uchida-Kobayashi S; Iwai S; Morikawa H; Enomoto M; Murakami Y; Tamori A; Kawada N
J Gastroenterol Hepatol; 2014 Sep; 29(9):1722-7. PubMed ID: 24730671
[TBL] [Abstract][Full Text] [Related]
18. Application of PET and PEt/CT imaging for cancer screening.
Chen YK; Ding HJ; Su CT; Shen YY; Chen LK; Liao AC; Hung TZ; Hu FL; Kao CH
Anticancer Res; 2004; 24(6):4103-8. PubMed ID: 15736459
[TBL] [Abstract][Full Text] [Related]
19. Analysis of various malignant neoplasms detected by FDG-PET cancer screening program: based on a Japanese Nationwide Survey.
Minamimoto R; Senda M; Terauchi T; Jinnouchi S; Inoue T; Iinuma T; Inoue T; Ito K; Iwata H; Uno K; Oku S; Oguchi K; Tsukamoto E; Nakashima R; Nishizawa S; Fukuda H; Murano T; Yoshida T
Ann Nucl Med; 2011 Jan; 25(1):45-54. PubMed ID: 20953985
[TBL] [Abstract][Full Text] [Related]
20. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
